Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for NatureWise Biotech & Medicals Corporation (4732:TWSE), powered by AI.
NatureWise Biotech & Medicals Corporation is currently trading at $17.70. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for NatureWise Biotech & Medicals Corporation on Alpha Lenz.
View NatureWise Biotech & Medicals Corporation's valuation metrics on Alpha Lenz.
“NatureWise Biotech & Medicals Corporation's ROE is -13.5%. Explore profitability and growth together.”
Ask for details →NatureWise Biotech & Medicals Corporation is a Taiwan-based biotechnology company specializing in the research, development, and commercialization of therapeutic drugs and nutraceuticals. Its primary focus lies in developing pharmaceutical products for both preventive and therapeutic use, notably including LipoCol Forte, a capsule addressing hypercholesterolemia and hypertriglyceridemia, as well as NBM-BMX, an oral softgel formulated for cancer treatment. The company also markets health supplements such as PPL Taiwan green propolis. Operating within the pharmaceuticals and medical research sector, NatureWise serves primarily the Taiwanese market but also records sales across other Asian countries such as Mainland China, Japan, Singapore, and Malaysia. Founded in 2000 and headquartered in Taipei, the organization supports both Western and Chinese medicine, reflecting a diverse approach to healthcare solutions. With a lean team of around 32 employees, NatureWise Biotech & Medicals Corporation plays a notable role in Taiwan's life sciences ecosystem, focusing on innovation in pharmaceuticals and contributing to global healthcare developments.
“NatureWise Biotech & Medicals Corporation's ROE is -13.5%. Explore profitability and growth together.”
Ask for details →NatureWise Biotech & Medicals Corporation (ticker: 4732) is a company listed on TWSE in the Healthcare sector (Biotechnology).
The current price is 17.7 with a P/E ratio of -x and P/B of -x.
ROE is -13.52% and operating margin is -60.45%. Annual revenue is $177M.